Davita (NYSE:DVA) Earns “Hold” Rating from Raymond James

Davita (NYSE:DVA)‘s stock had its “hold” rating reiterated by research analysts at Raymond James in a note issued to investors on Tuesday, AnalystRatings.com reports.

DVA has been the subject of a number of other research reports. ValuEngine raised Davita from a “strong sell” rating to a “sell” rating in a research report on Tuesday, September 1st. SunTrust Banks upped their price objective on shares of Davita from $90.00 to $100.00 and gave the stock a “hold” rating in a report on Friday, July 31st. Finally, Zacks Investment Research upgraded shares of Davita from a “hold” rating to a “buy” rating and set a $100.00 target price on the stock in a report on Monday, August 3rd. One investment analyst has rated the stock with a sell rating, six have given a hold rating and three have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $77.83.

Shares of DVA traded up $2.05 during midday trading on Tuesday, reaching $89.84. 2,959,200 shares of the stock were exchanged, compared to its average volume of 1,295,177. The company has a market cap of $10.71 billion, a price-to-earnings ratio of 14.17 and a beta of 1.20. The company has a quick ratio of 1.33, a current ratio of 1.35 and a debt-to-equity ratio of 3.38. Davita has a 12-month low of $54.08 and a 12-month high of $92.16. The firm has a 50 day simple moving average of $86.15 and a 200-day simple moving average of $80.14.

Davita (NYSE:DVA) last released its quarterly earnings data on Thursday, July 30th. The company reported $1.95 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.30 by $0.65. The business had revenue of $2.88 billion during the quarter, compared to analyst estimates of $2.91 billion. Davita had a net margin of 7.20% and a return on equity of 40.78%. Research analysts expect that Davita will post 6.75 earnings per share for the current fiscal year.

In other news, Director Pamela M. Arway sold 578 shares of the business’s stock in a transaction dated Monday, August 24th. The shares were sold at an average price of $87.02, for a total transaction of $50,297.56. Following the transaction, the director now owns 19,239 shares in the company, valued at approximately $1,674,177.78. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 1.00% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. CIBC Asset Management Inc raised its stake in shares of Davita by 1.3% in the 2nd quarter. CIBC Asset Management Inc now owns 10,462 shares of the company’s stock valued at $828,000 after buying an additional 138 shares in the last quarter. M&T Bank Corp boosted its holdings in Davita by 2.6% during the second quarter. M&T Bank Corp now owns 5,604 shares of the company’s stock valued at $443,000 after purchasing an additional 143 shares in the last quarter. CSat Investment Advisory L.P. grew its stake in shares of Davita by 16.0% in the 2nd quarter. CSat Investment Advisory L.P. now owns 1,063 shares of the company’s stock valued at $84,000 after purchasing an additional 147 shares during the period. Hanseatic Management Services Inc. raised its holdings in shares of Davita by 1.6% in the 2nd quarter. Hanseatic Management Services Inc. now owns 10,303 shares of the company’s stock worth $815,000 after buying an additional 165 shares in the last quarter. Finally, Cozad Asset Management Inc. lifted its position in shares of Davita by 3.9% during the 2nd quarter. Cozad Asset Management Inc. now owns 6,750 shares of the company’s stock worth $534,000 after buying an additional 255 shares during the period. Hedge funds and other institutional investors own 91.56% of the company’s stock.

Davita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.

Recommended Story: Cost of Capital Explained

Analyst Recommendations for Davita (NYSE:DVA)

Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.